Biodesix Targets 2028 Launch for Imaging-Based Lung Nodule Risk Test

By Public Technologies
  • Biodesix added digital diagnostics to its lung testing strategy, targeting a 2028 commercial launch for its first imaging-based lung nodule risk test.
  • Developed with Vanderbilt University and Vanderbilt Health, the test aims to improve lung cancer risk assessment alongside the Nodify Lung blood-testing portfolio.
  • Initial performance results will be presented at the RSNA annual meeting on December 3, 2026.
  • The prospective STRATIFY study is expected to begin in the fourth quarter of 2026, matching blood and imaging biomarkers with clinical outcomes.
  • The study will support clinical validation, reimbursement evidence and future multimodal diagnostic development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodesix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190600PRIMZONEFULLFEED9848106) on October 19, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.